Immunomodulatory effects of anti-estrogenic drugs

Acta Pharmaceutica

Volumn 62, Issue 2, 2012, Pages 141-155

  Ray, Amitabha ^a   Ficek, Monica ^a  

^a SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

Author keywords

aromatase inhibitors; breast cancer; immunopharmacology; SERMs; tamoxifen

Indexed keywords

ACOLBIFENE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ARZOXIFENE; BUSERELIN; CENTCHROMAN; DROLOXIFENE; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; GONADORELIN AGONIST; GOSERELIN; IDOXIFENE; IMMUNOMODULATING AGENT; LASOFOXIFENE; LETROZOLE; LEUPRORELIN; NAFARELIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOLACTONE; TOREMIFENE; TRIPTORELIN; UNINDEXED DRUG; VOROZOLE;

ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DERMATOMYOSITIS; DRUG EFFECT; ENDOMETRIOSIS; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; LOW DRUG DOSE; LUNG CARCINOMA; NATURAL KILLER CELL; NONHUMAN; OVARY CARCINOMA; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

EID: 84863471228     PISSN: 13300075     EISSN: 18469558     Source Type: Journal    
DOI: 10.2478/v10007-012-0012-3     Document Type: Review

References (85)

1. A. Ray and A. B. Mitra, Estrogen and breast cancer, ICMR Bull. 33 (2003) 13-24.
2. M. N. Okobia and C. H. Bunker, Epidemiological risk factors for breast cancer-a review, Niger. J. Clin. Pract. 8 (2005) 35-42.
3. T. Suzuki, Y. Miki, N. Ohuchi and H. Sasano, Intratumoral estrogen production in breast carcinoma: significance of aromatase, Breast Cancer 15 (2008) 270-277; DOI: 10.1007/s12282-008-0062-z.
4. I. Czajka-Oraniec and E. R. Simpson, Aromatase research and its clinical significance, Endo-krynol. Pol. 61 (2010) 126-134.
5. W. C. Park and V. C. Jordan, Selective estrogen receptor modulators (SERMs) and their roles in breast cancer prevention, Trends Mol. Med. 8 (2002) 82-88; DOI: 10.1016/S1471-4914(02)02282-7.
6. G. T. Beatson, On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new treatment with illustrative cases, Lancet 2 (1896) 104-107; DOI: 10.1016/S0140-6736 (01) 72384-7.
7. W. R. Miller, Oestrogens and breast cancer: biological considerations, Br. Med. Bull. 47 (1991) 470-483.
8. V. C. Jordan and W. J. Gradishar, Hormonal Therapy for Breast Cancer, in The Cancer Handbook (Ed. M. R. Alison), Vol. 2, Nature Publishing Group, London, 2002; pp. 1449-1464.
9. P. Lonning, C. Pfister, A. Martoni and C. Zamagni, Pharmacokinetics of third-generation aro-matase inhibitors, Semin. Oncol. 30 Suppl. 14 (2003) 23-32; DOI: 10.1016/S0093-7754(03)00305-1.
10. R. Stuart-Harris and A. Davis, Optimal adjuvant endocrine therapy for early breast cancer, Women's Health 6 (2010) 383-398; DOI: 10.2217/whe.10.25.
11. T. Delozier, Hormonal treatment in breast cancer, J. Gynecol. Obstet. Biol. Reprod. 39, Suppl. 8 (2010) F71-78; DOI: 10.1016/j.jgyn.2010.10.004.
12. D. P. McDonnell and S. E. Wardell, The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer, Curr. Opin. Pharmacol. 10 (2010) 620-628; DOI: 10.1016/j.coph.2010.09.007.
13. F. Lumachi, G. Luisetto, S. M. Basso, U. Basso, A. Brunello and V. Camozzi, Endocrine therapy of breast cancer, Curr. Med. Chem. 18 (2011) 513-522; DOI: 10.2174/092986711794480177.
14. A. Thomsen and J. M. Kolesar, Chemoprevention of breast cancer, Am. J. Health Syst. Pharm. 65 (2008) 2221-2228; DOI: 10.2146/ajhp070663.
15. C. Rivera-Guevara and J. Camacho, Tamoxifen and its new derivatives in cancer research, Recent Pat. Anticancer Drug Discov. 6 (2011) 237-245.
16. R. Weinshilboum, Pharmacogenomics of endocrine therapy in breast cancer, Adv. Exp. Med. Biol. 630 (2008) 220-231; DOI: 10.1007/978-0-387-78818-0-14.
17. H. Brauch, T. E. Mürdter, M. Eichelbaum and M. Schwab, Pharmacogenomics of tamoxifen therapy, Clin. Chem. 55 (2009) 1770-1782; DOI: 10.1373/clinchem.2008.121756.
18. R. Clarke, F. Leonessa, J. N. Welch and T. C. Skaar, Cellular and molecular pharmacology of antiestrogen action and resistance, Pharmacol. Rev. 53 (2001) 25-71.
19. A. Ring and M. Dowsett, Mechanisms of tamoxifen resistance, Endocr. Relat. Cancer 11 (2004) 643-658; DOI: 10.1677/erc.1.00776.
20. C. M. Joffroy, M. B. Buck, M. B. Stope, S. L. Popp, K. Pfizenmaier and C. Knabbe, Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer, Cancer Res. 70 (2010) 1314-1322; DOI: 10.1158/0008-5472.CAN-09-3292.
21. S. Rotstein, H. Blomgren, B. Petrini, J. Wasserman and L. V. von Stedingk, Influence of adjuvant ta-moxifen on blood lymphocytes, Breast Cancer Res. Treat. 12 (1988) 75-79; DOI: 10.1007/BF01805743.
22. E. Robinson, D. Rubin, T. Mekori, R. Segal and S. Pollack, In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer, Cancer Immunol. Immunother. 37 (1993) 209-212; DOI: 10.1007/BF01525437.
23. P. Mallmann and D. Krebs, Effect of tamoxifen on parameters of cell-mediated immunity in post-menopausal patients with breast carcinoma, Zbl. Gynakol. 113 (1991) 689-696.
24. J. Lukac, Z. Kusic, D. Kordic, M. Koncar and A. Bolanca, Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen, Breast Cancer Res. Treat. 29 (1994) 279-285; DOI: 10.1007/BF00666482.
25. M. E. Sabbioni, M. Castiglione, C. Hürny, H. P. Siegrist, M. Bacchi, J. Bernhard, B. Thürlimann, H. Bonnefoi, L. Perey, A. Goldhirsch and H. J. Senn, Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients, Support. Care Cancer 7 (1999) 149-153; DOI: 10.1007/s005200050245.
26. E. Baral, E. Nagy, G. V. Krepart, R. J. Lotocki, H. W. Unruh and I. Berczi, Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells, Anticancer Res. 20 (2000) 2027-2031.
27. E. Baral, E. Nagy, L. Kangas and I. Berczi, Anti-estrogens enhance the therapeutic effect of lym-phokine-activated killer cells on the P815 murine mastocytoma, Int. J. Cancer 67 (1996) 580-585; DOI: 10.1002/(SICI)1097- 0215(19960807).
28. E. Baral, E. Nagy, L. Kangas and I. Berczi, Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens, Anticancer Res. 17 (1997) 3653-3658.
29. S. Kumru, F. M. Yildiz, A. Godekmerdan, S. Kutlu, B. Yilmaz and B. Gurates, Effects of raloxi-fene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial, Arch. Gynecol. Obstet. 277 (2008) 489-493; DOI: 10.1007/s00404-007-0521-3.
30. Y. Zhang, S. Saha, G. Rosenfeld, J. Gonzalez, K. P. Pepeljugoski and E. Peeva, Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB/W F1 mice, J. Rheumatol. 37 (2010) 1646-1657; DOI: 10.3899/jrheum.090911.
31. G. Nalbandian, V. Paharkova-Vatchkova, A. Mao, S. Nale and S. Kovats, The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation, J. Immunol. 175 (2005) 2666-2675.
32. M. A. García-Pérez, R. Del Val, I. Noguera, C. Hermenegildo, B. Pineda, A. Martinez-Romero and A. Cano, Estrogen receptor agonists and immune system in ovariectomized mice, Int. J. Immunopathol. Pharmacol. 19 (2006) 807-819.
33. M. C. Erlandsson, E. Gomori, M. Taube and H. Carlsten, Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice, Cell. Immunol. 205 (2000) 103-109; DOI: 10.1006/cimm.2000.1719.
34. H. Masuoka, M. Mori, N. Nomura, M. Sakurai, K. Yoshida, N. Usuda, H. Shirai, I. Shimokawara and K. Asaishi, Assessment of post-administration body distribution of toremifene and tamoxi-fen, and their administration regimens, Jpn. J. Cancer. Res. 29 (2002) 881-887.
35. S. M. Haeryfar, E. Nagy, E. Baral, G. V. Krepart, R. J. Lotocki and I. Berczi, Antiestrogens affect both pathways of killer cell-mediated oncolysis, Anticancer Res. 20 (2000) 1849-1853.
36. J. Komi and O. Lassila, Antioestrogens enhance tumour necrosis factor receptor 2 (TNF-R2) expression and TNF-R2-mediated proliferation in activated T cells, Scand. J. Immunol. 48 (1998) 254-260; DOI: 10.1046/j.1365-3083.1998. 00388.x.
37. J. Teodorczyk-Injeyan, M. Cembrzynska-Nowak, S. Lalani and J. A. Kellen, Modulation of biological responses of normal human mononuclear cells by antiestrogens, Anticancer Res. 13 (1993) 279-283.
38. J. A. Kellen, The effect of toremifene on the expression of some genes in human mononuclear cells, In Vivo 9 (1995) 215-217.
39. L. S. Järvinen, S. Pyrhönen, K. J. Kairemo and T. Paavonen, The effect of anti-oestrogens on cy-tokine production in vitro, Scand. J. Immunol. 44 (1996) 15-20; DOI: 10.1046/j.1365-3083.1996. d01-85.x.
40. P. Pal, J. K. Kanaujiya, S. Lochab, S. B. Tripathi, M. L. Bhatt, P. K. Singh, S. Sanyal and A. K. Trivedi, 2-D gel electrophoresis-based proteomic analysis reveals that ormeloxifen induces G0-G1 growth arrest and ERK-mediated apoptosis in chronic myeloid leukemia cells K562, Proteo-mics 11 (2011) 1517-1529; DOI: 10.1002/pmic.201000720.
41. L. Thomas, M. Asad, H. J. Hrishikeshavan and G. K. Chandrakala, Effect of centchroman on cellular and humoral immunity, Indian J. Physiol. Pharmacol. 51 (2007) 387-394.
42. A. Purohit, A. Singh, M. W. Ghilchik, O. Serlupi-Crescenzi and M. J. Reed, Inhibition of IL-6+ IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts, Br. J. Cancer 88 (2003) 630-635; DOI: 10.1038/sj.bjc.6600785.
43. P. G. Morris, C. A. Hudis, D. Giri, M. Morrow, D. J. Falcone, X. K. Zhou, B. Du, E. Brogi, C. B. Crawford, L. Kopelovich, K. Subbaramaiah and A. J. Dannenberg, Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer, Cancer Prev. Res. 4 (2011) 1021-1029; DOI: 10.1158/1940-6207.CAPR-11-0110.
44. J. Berry, B. J. Green and D. S. Matheson, Modulation of natural killer cell activity in stage I post-menopausal breast cancer patients on low-dose aminoglutethimide, Cancer Immunol. Immuno-ther. 24 (1987) 72-75; DOI: 10.1007/BF00199836.
45. H. van Dijk and H. E. Jacobse-Geels, Evidence for the involvement of corticosterone in the ontogeny of the cellular immune apparatus of the mouse, Immunology 35 (1978) 637-642.
46. M. D. Coleman, L. F. Khalaf and P. J. Nicholls, Aminoglutethimide-induced leukopenia in a mouse model: effects of metabolic and structural determinants, Environ. Toxicol. Pharmacol. 15 (2003) 27-32; DOI: 10.1016/j.etap.2003.08.003.
47. M. J. Cannon, M. G. Petroff and J. L. Pate, Effects of prostaglandin F2alpha and progesterone on the ability of bovine luteal cells to stimulate T lymphocyte proliferation, Biol. Reprod. 69 (2003) 695-700; DOI: 10.1095/?biolreprod.103.017590.
48. D. P. Braun, K. A. Crist, F. Shaheen, E. D. Staren, S. Andrews and J. Parker, Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity, Am. J. Surg. 190 (2005) 570-571; DOI: 10.1016/j.amjsurg.2005.06.013.
49. C. P. Schneider, E. A. Nickel, T. S. Samy, M. G. Schwacha, W. G. Cioffi, K. I. Bland and I. H. Chaudry, The aromatase inhibitor, 4- hydroxyandrostenedione, restores immune responses following trauma-hemorrhage in males and decreases mortality from subsequent sepsis, Shock 14 (2000) 347-353.
50. J. Morales-Montor, C. Hallal-Calleros, M. C. Romano and R. T. Damian, Inhibition of p-450 aro-matase prevents feminisation and induces protection during cysticercosis, Int. J. Parasitol. 32 (2002) 1379-1387; DOI: 10.1016/S0020-7519(02)00130-3.
51. T. Watanabe, M. Sano, M. Toi, T. Saeki, K. Kanda, S. Miura, H. Inaji, H. Sono, H. Saeki, R. Ni-shimura and Y. Fujita, Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents, Gan. To. Kagaku. Ryoho. (Cancer & Chemotherapy) 29 (2002) 1211-1221.
52. M. Mello-Grand, V. Singh, C. Ghimenti, M. Scatolini, L. Regolo, E. Grosso, A. Zambelli, G. A. Da Prada, L. Villani, V. Fregoni, P. Baiardi, S. Marsoni, W. R. Miller, A. Costa and G. Chiorino, Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer, Breast Cancer Res. Treat. 121 (2010) 399-411; DOI: 10.1007/s10549-010-0887-y.
53. B. Karagöz, O. Bilgi, A. Alacacioǧlu, A. Ozgün, O. Sayan, A. A. Erikçi and E. G. Kandemir, Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer, Med. Oncol. 27 (2010) 199-202; DOI: 10.1007/s12032-009-9191-2.
54. D. Generali, G. Bates, A. Berruti, M. P. Brizzi, L. Campo, S. Bonardi, A. Bersiga, G. Allevi, M. Milani, S. Aguggini, L. Dogliotti, A. H. Banham, A. L. Harris, A. Bottini and S. B. Fox, Immuno-modulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients, Clin. Cancer Res. 15 (2009) 1046-1051; DOI: 10.1158/1078-0432.CCR-08-1507.
55. Q. Zhang, D. Tang and H. Zhao, Immunological therapies can relieve aromatase inhibitor-reated joint symptoms in breast cancer survivors, Am. J. Clin. Oncol. 33 (2010) 557-560; DOI: 10.1097/COC.0b013e3181cae782.
56. J. Wang, Q. Zhang, S. Jin, M. Feng, X. Kang, S. Zhao, S. Liu and W. Zhao, Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis, Exp. Gerontol. 44 (2009) 398-405; DOI: 10.1016/j.exger.2009.03.003.
57. M. N. Singh, P. L. Martin-Hirsch and F. L. Martin, The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century, Med. Sci. Monit. 14 (2008) 144-148.
58. J. Komi and O. Lassila, Nonsteroidal anti-estrogens inhibit the functional differentiation of human monocyte-derived dendritic cells, Blood 95 (2000) 2875-2882.
59. J. Komi, M. Möttönen, R. Luukkainen and O. Lassila, Non-steroidal anti-oestrogens inhibit the differentiation of synovial macrophages into dendritic cells, Rheumatology 40 (2001) 185-191; DOI: 10.1093/rheumatology/40.2.185.
60. S. Behjati and M. H. Frank, The effects of tamoxifen on immunity, Curr. Med. Chem. 16 (2009) 3076-3080.
61. B. F. Bebo Jr, B. Dehghani, S. Foster, A. Kurniawan, F. J. Lopez and L. S. Sherman, Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis, Glia 57 (2009) 777-790; DOI: 10.1002/glia.20805.
62. D. Sereda and V. P. Werth, Improvement in dermatomyositis rash associated with the use of antiestrogen medication, Arch. Dermatol. 142 (2006) 70-72.
63. M. Babina, F. Kirn, D. Hoser, D. Ernst, W. Rohde, T. Zuberbier and M. Worm, Tamoxifen counteracts the allergic immune response and improves allergen-induced dermatitis in mice, Clin. Exp. Allergy 40 (2010) 1256-1265; DOI: 10.1111/j.1365-2222.2010.03472.x.
64. W. M. Wu, J. L. Suen, B. F. Lin and B. L. Chiang, Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice, Immunology 100 (2000) 110-118; DOI: 10.1046/j.1365-2567.2000.00998.x.
65. W. M. Wu, B. F. Lin, Y. C. Su, J. L. Suen and B. L. Chiang, Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice, Scand. J. Immunol. 52 (2000) 393-400; DOI: 10.1046/j.1365-3083.2000. 00789.x.
66. Z. M. Sthoeger, H. Zinger and E. Mozes, Beneficial effects of the anti-oestrogentamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies, Ann. Rheum. Dis. 62 (2003) 341-346; DOI: 10.1136/ard.62.4.341.
67. E. Peeva, J. Venkatesh and B. Diamond, Tamoxifen blocks estrogen-induced B cell maturation but not survival, J. Immunol. 175 (2005) 1415-1423.
68. Y. Y. Dhaher, B. D. Greenstein, M. A. Khamashta and G. R. Hughes, Effects of oestradiol and the oestrogen antagonist Ici 182,780 on the delayed type hypersensitivity (DTH) index and on serum levels of IgM and IgG in ovariectomisedBalb/C and MRL/Mp-Lpr/Lpr mice, a model of systemic lupus erythematosus (SLE), Autoimmunity 33 (2001) 237-243.
69. V. Paharkova-Vatchkova, R. Maldonado and S. Kovats, Estrogen preferentially promotes the differentiation of CD11c+ CD11b(intermediate) dendritic cells from bone marrow precursors, J. Immunol. 172 (2004) 1426-1436.
70. S. Cuzzocrea, S. Bruscoli, C. Crisafulli, E. Mazzon, M. Agostini, C. Muià, E. Esposito, R. Di Vir-gilio, R. Meli, E. Vegeto, A. Maggi and C. Riccardi, Estrogen receptor antagonist fulvestrant (ICI 182,780) inhibits the anti-inflammatory effect of glucocorticoids, Mol. Pharmacol. 71 (2007) 132-144; DOI: 10.1124/mol.106.029629.
71. N. I. Abdou, V. Rider, C. Greenwell, X. Li and B. F. Kimler, Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial, J. Rheumatol. 35 (2008) 797.
72. S. N. Umathe, P. V. Dixit, M. M. Wanjari and M. P. Ullewar, Leuprolide\a GnRH agonist\prevents restraint stress-induced immunosuppression via sex steroid-independent peripheral mechanism in mice, Int. Immunopharmacol. 8 (2008) 71-79; DOI: 10.1016/j.intimp.2007.10.011.
73. G. L. Goldberg, C. G. King, R. A. Nejat, D. Y. Suh, O. M. Smith, J. C. Bretz, R. M. Samstein, J. A. Dudakov, A. P. Chidgey, S. Chen-Kiang, R. L. Boyd and M. R. van den Brink, Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation, J. Immunol. 182 (2009) 5846-5854; DOI: 10.4049/?jimmunol.0801458.
74. K. Szyllo, H. Tchorzewski, M. Banasik, E. Glowacka, P. Lewkowicz and A. Kamer-Bartosinska, The involvement of T lymphocytes in the pathogenesis of endometriotic tissues overgrowth in women with endometriosis, Mediators Inflamm. 12 (2003) 131-138; DOI: 10.1080/0962935031000134842.
75. H. N. Ho, H. F. Chen, S. U. Chen, K. H. Chao, Y. S. Yang, S. C. Huang, T. Y. Lee and T. J. Gill 3rd., Gonadotropin releasing hormone (GnRH) agonist induces down-regulation of the CD3+ CD25+ lymphocyte subpopulation in peripheral blood, Am. J. Reprod. Immunol. 33 (1995) 243-252.
76. N. Umesaki, T. Tanaka, M. Miyama, K. Mizuno, N. Kawamura and S. Ogita, Increased natural killer cell activities in patients treated with gonadotropin releasing hormone agonist, Gynecol. Obstet. Invest. 48 (1999) 66-68; DOI: 10.1159/000010137.
77. G. G. Garzetti, A. Ciavattini, M. Provinciali, M. Muzzioli, G. Di Stefano and N. Fabris, Natural cytotoxicity and GnRH agonist administration in advanced endometriosis: positive modulation on natural killer activity, Obstet. Gynecol. 88 (1996) 234-240; DOI: 10.1016/0029-7844(96)00146-9.
78. M. E. Sabbioni, H. P. Siegrist, M. Bacchi, J. Bernhard, M. Castiglione, B. Thürlimann, H. Bon-nefoi, L. Perey, R. Herrmann, A. Goldhirsch and C. Hürny, Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment, Breast Cancer Res. Treat. 59 (2000) 279-287; DOI: 10.1023/A:1006379925343.
79. A. Ray, V. Gupta, R. Kant, R. Yadav, A. K. Bahadur, S. L. D. Naik, B. K. Sharma and N. S. Mur-thy, T-lymphocytes in breast cancer: association with prognostic factors and response to treatment, Ann. Natl. Acad. Med. Sci. 39 (2003) 105-115.
80. E. Pavoni, G. Monteriù, D. Santapaola, F. Petronzelli, A. M. Anastasi, A. Pelliccia, V. D'Alessio, R. De Santis and O. Minenkova, Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells, BMC. Biotechnol. 7 (2007) 70; DOI: 10.1186/1472-6750-7-70.
81. V. N. Kristensen, C. J. Vaske, J. Ursini-Siegel, P. Van Loo, S. H. Nordgard, R. Sachidanandam, T. Sørlie, F. Wärnberg, V. D. Haakensen, A. Helland, B. Naume, C. M. Perou, D. Haussler, O. G. Troyanskaya and A. L. Børresen-Dale, Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling, Proc. Natl. Acad. Sci. U.S.A. 109 (2012) 2802-2807; DOI: 10.1073/pnas.1108781108.
82. S. C. Baumgarten and J. Frasor, Mini review: Inflammation: An instigator of more aggressive estrogen receptor (ER) positive breast cancers, Mol. Endocrinol. 26 (2012) 360-371; DOI: 10.1210/me.2011-1302.
83. C. K. Osborne and R. Schiff, Mechanisms of endocrine resistance in breast cancer, Annu. Rev. Med. 62 (2011) 233-247; DOI: 10.1146/annurev-med-070909- 182917.
84. M. E. Grossmann, A. Ray, K. J. Nkhata, D. A. Malakhov, O. P. Rogozina, S. Dogan and M. P. Cleary, Obesity and breast cancer: status of leptin and adiponectin in pathological processes, Cancer Metastasis Rev. 29 (2010) 641-653; DOI: 10.1007/s10555-010-9252-1.
85. H. S. Kim, C. K. Yom, H. J. Kim, J. W. Lee, J. H. Sohn, J. H. Kim, Y. L. Park and S. H. Ahn, Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy, Breast Cancer Res. Treat. 121 (2010) 777-788; DOI: 10.1007/s10549-009-0560-5.